Price transparency compliance and variation for proton therapy in the United States
Cancer Lett
.
2026 Mar 1:640:218260.
doi: 10.1016/j.canlet.2026.218260.
Epub 2026 Jan 16.
Authors
Kasey R Cargill
1
,
Noah M Feder
2
,
Tyler Wilhite
1
,
Walid F Gellad
2
,
Heath D Skinner
1
,
Yvonne M Mowery
1
,
Christopher T Wilke
3
Affiliations
1
Department of Radiation Oncology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
2
Division of General Internal Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
3
Department of Radiation Oncology, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Electronic address: wilkect@upmc.edu.
PMID:
41548863
DOI:
10.1016/j.canlet.2026.218260
No abstract available
Keywords:
CMS; Financial toxicity; Policy; Price transparency; Proton therapy.